PITTSBURGH--(BUSINESS WIRE)--invivodata inc., the industry leader in electronic patient reported outcomes (ePRO) solutions and services for global clinical research, today announced that its eDiary solution, DiaryPRO®, captured some of the primary efficacy data that supported the recent U.S. Food and Drug Administration’s (FDA) approval of Alcon Inc.’s PATANASE® (Olopatadine Hydrochloride) Nasal Spray, indicated for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older.
